Hematopoietic Stem Cell Transplantation Activity in China 2020–2021 During the SARS-CoV-2 Pandemic: A Report From the Chinese Blood and Marrow Transplantation Registry Group
暂无分享,去创建一个
Xiao-hui Zhang | Lanping Xu | Yi Luo | He Huang | E. Jiang | L. Xia | Daihong Liu | Yongxian Lai | Yong-Ping Song | Zi-min Sun | C. Luo | De-pei Wu | Xi Zhang | D. Lu | T. Niu | Nainong Li | Si-xi Liu | Qi-fa Liu | Xiao-Jun Huang | Yu Yu | Xian-Min Song | Yi-cheng Zhang | Xiao-wen Tang | Y. Lai | Ting Niu
[1] I. Yakoub-Agha,et al. Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey , 2022, Bone Marrow Transplantation.
[2] Shunqing Wang,et al. Long-term follow-up of haploidentical transplantation in relapsed/refractory severe aplastic anemia: a multicenter prospective study. , 2022, Science bulletin.
[3] M. Krem,et al. Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia , 2021, Blood advances.
[4] He Huang,et al. The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update , 2021, Journal of Hematology & Oncology.
[5] He Huang,et al. Hematopoietic stem cell transplantation activity in China 2019: a report from the Chinese Blood and Marrow Transplantation Registry Group , 2021, Bone Marrow Transplantation.
[6] N. Kröger,et al. Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT , 2021, Journal of Hematology & Oncology.
[7] M. Aljurf,et al. Clinical course and outcomes of COVID‐19 in hematopoietic cell transplant patients, a regional report from the Middle East , 2021, Bone Marrow Transplantation.
[8] Yu Wang,et al. G-CSF-Primed Peripheral Blood Stem Cell Haploidentical Transplantation Could Achieve Satisfactory Clinical Outcomes for Acute Leukemia Patients in the First Complete Remission: A Registered Study , 2021, Frontiers in Oncology.
[9] A. Nagler,et al. How Do We Manage Hematopoietic Cell Transplant during the SARS-CoV-2 Pandemic? , 2021, Acta Haematologica.
[10] A. Velardi,et al. Haplo‐identical or mismatched unrelated donor hematopoietic cell transplantation for Fanconi anemia: Results from the Severe Aplastic Anemia Working Party of the EBMT , 2021, American journal of hematology.
[11] S. Seitz,et al. Stem cell donor registry activities during the COVID-19 pandemic: a field report by DKMS , 2020, Bone Marrow Transplantation.
[12] W. Wood,et al. Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Commi , 2020, Biology of Blood and Marrow Transplantation.
[13] S. Montoto,et al. Correction: The challenge of COVID-19 and hematopoietic cell transplantation: EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy , 2020, Bone Marrow Transplantation.
[14] S. Montoto,et al. The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy. , 2020, Bone marrow transplantation.
[15] S. Montoto,et al. The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy , 2020, Bone Marrow Transplantation.
[16] M. Labopin,et al. Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia , 2020, Leukemia.
[17] M. Labopin,et al. Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT , 2020, Journal of Hematology & Oncology.
[18] S. Montoto,et al. Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019 , 2019, Bone Marrow Transplantation.
[19] Libo Zhao,et al. Bone marrow versus peripheral blood as a graft source for haploidentical donor transplantation in adults using post-transplant cyclophosphamide-A systematic review and meta-analysis. , 2019, Critical reviews in oncology/hematology.
[20] He Huang,et al. The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China—recommendations from the Chinese Society of Hematology , 2018, Journal of Hematology & Oncology.
[21] L. Xu,et al. A review of hematopoietic cell transplantation in China: data and trends during 2008–2016 , 2017, Bone Marrow Transplantation.
[22] Shunqing Wang,et al. Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant , 2017, Journal of Hematology & Oncology.
[23] S. Theurich,et al. Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults. , 2014, The Cochrane database of systematic reviews.
[24] A. Gratwohl,et al. Hematopoietic stem cell transplantation: a global perspective. , 2010, JAMA.
[25] Edward A Copelan,et al. Hematopoietic stem-cell transplantation. , 2006, The New England journal of medicine.